Source - RNS
RNS Number : 4253L
Clinigen Group plc
03 October 2016
 

3 October 2016

 

 

Director's Share Dealing

 

Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services group, announces that it was notified on 30 September 2016 that on 28 September 2016, Simon Estcourt, the Chief Strategy Officer, sold 5,100 ordinary shares of 0.1 pence each in the Company at a price of 728 pence per share.

 

Following these transactions, Mr Estcourt's total beneficial interest in the Company is 167,139 ordinary shares, representing approximately 0.15 per cent of the current issued share capital.

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Simon Estcourt

2

Reason for the notification

a)

Position/status

Chief Strategy Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Clinigen Group plc

b)

Legal Entity Identifier

N/A

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

Ordinary shares of 0.1 pence each

 

 

 

GB00B89J2419

b)

Nature of the transaction

Sale of shares

c)

Currency

GBP

d)

Price(s) and volume(s)

Price(s)

Volume(s)

728p

5,100

 

e)

Aggregated information

- Aggregated volume

- Price

- Aggregated total

 

 

5,100

728p

£37,128.00

f)

Date of the transaction

28 September 2016

g)

Place of the transaction

London Stock Exchange, AIM

 

 

-Ends-

 

 

Contact Details

 

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer


Shaun Chilton, Group Deputy Chief Executive Officer

Martin Abell, Group Chief Financial Officer




Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Tom Ballard  (Corporate Broking)


 


Peel Hunt LLP - Joint Broker

Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden




Instinctif Partners (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell / Jayne Crook / Emma Barlow

Email: [email protected]

 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time.

 

The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

 

Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.

 

The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).

 

Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.

 

For more information, please visit www.clinigengroup.com  


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHLLFETAEIIVIR

Related Charts

Clinigen Group (CLIN)

-10.50p (-1.45%)
delayed 18:15PM